Brenda J. Weigel

Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study

Yaël P. Mossé, Megan S. Lim, Stephan D. Voss et al. · The Lancet Oncology · 2013 · 701 citations · Full text

Medicine, Oncology, Pediatrics +11

Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia

Qing Zhou, Meghan E. Munger, Rachelle G. Veenstra et al. · Blood · 2011 · 679 citations · Full text

Life Sciences, Immunology, Oncology +14

Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children’s Oncology Group Study

Yaël P. Mossé, Stephan D. Voss, Megan S. Lim et al. · Journal of Clinical Oncology · 2017 · 403 citations · Full text

Medicine, Oncology, Pharmacology +15

Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1–2 trial

Kara L. Davis, Elizabeth Fox, Melinda S. Merchant et al. · The Lancet Oncology · 2020 · 336 citations · Full text

Medicine, Oncology, Pharmacology +16

Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia

Qing Zhou, Meghan E. Munger, Steven L. Highfill et al. · Blood · 2010 · 285 citations · Full text

Life Sciences, Immunology, Oncology +14